Home News Archives - AKAVA THERAPEUTICS

AKAVA THERAPEUTICS > News > Home News

Akava Therapeutics, Inc. shares recent data suggesting that AKV9 acts on a common mechanism involved in both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS)

Akava Therapeutics, Inc. congratulates SAB Chair Dr. Hande Ozdinler, Founder Dr. Richard B. Silverman, and Dr. William Klein on their recent grant of $7.3 million from the National Institute on Aging to investigate AKV9 in neurodegenerative diseases

National Institute on Aging invests an additional $7.3 million into NU-9

Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis

Richard B. Silverman elected to the National Academy of Sciences

Drug Hunter Interview

Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.